Activated coagulation factor IX (FIXa) is a weak protease until it assembles with its cofactor VIIIa (FVIIIa), calcium, and an anionic membrane into the intrinsic Xase complex, which activates factor X roughly a million-fold faster than isolated FIXa. Crystal structures of superactive FIXa mutants (Zögg and Brandstetter, 2009) proposed an internal-brake mechanism — a His185–Tyr225 hydrogen bond and the 186-EGG-188 loop occluding a canonical sodium-binding site, a 99-loop covering the substrate-binding cleft, and a stimulatory ethylene glycol site revealing active-site plasticity — and visualized calcium-linked communication lines, but only in inhibited crystals of engineered variants. The open problem is to establish, at structural, energetic, and kinetic resolution in solution and on membranes, how physiological partners (FVIIIa, membrane, substrate FX, and the ions Ca2+Ca^{2+}/Na+Na^{+}) relieve these brakes and drive FIXa's conformational activation: specifically, the atomic organization of the membrane-bound FVIIIa–FIXa complex, the interplay of sodium binding with cofactor binding and catalysis under physiological conditions, the fate of the ethylene-glycol-mimicked stabilizing groove in vivo, and the energetic couplings and temporal ordering of the conformational transitions that the 2009 crystallographic snapshots only localized.

Background

Blood coagulation is an enzyme cascade in which trypsin-like serine proteases (proteases with a His-Asp-Ser catalytic triad and a chymotrypsin-like fold) activate one another. Factor IX is a vitamin K-dependent zymogen whose mature protein consists of a Gla domain (a γ\gamma-carboxyglutamic-acid-rich module that binds Ca2+Ca^{2+} and anionic phospholipid membranes), two epidermal-growth-factor-like (EGF) domains, and a C-terminal serine protease domain. Upon proteolytic activation to the two-chain enzyme FIXa, it remains catalytically poor: processed FIXa alone is nearly silent toward its physiological substrate, factor X (FX). Only on assembly of the intrinsic Xase complex — FIXa plus its cofactor FVIIIa (the activated, labile heterotrimer derived from factor VIII), Ca2+Ca^{2+}, and an activated-platelet or phospholipid membrane surface — does FX activation accelerate by up to about 10610^{6}-fold, making the Xase complex the amplification engine of coagulation and the molecular lesion of both hemophilia A (FVIII deficiency) and hemophilia B (FIX deficiency).

Throughout this field, residue numbers in the protease domain use chymotrypsinogen numbering (the convention that assigns the catalytic Ser the number 195), so that homologous positions can be compared across thrombin, factor Xa (FXa), and FIXa. A hallmark of several coagulation proteases is an allosteric monovalent-cation site: in thrombin and FXa, a Na+Na^{+} ion is coordinated by backbone carbonyls of the 184A/185 and 221A/224 region (the so-called 186/220-loop region) and shifts the enzyme between fast and slow conformational states. Sequence comparisons and biochemical data predict the same site in FIXa, yet in early FIXa crystal structures — including the first FIXa structure (Brandstetter et al., 1995), which revealed a collapsed substrate-binding cleft with the 99-loop partially occluding it — the site was seen unoccupied. Zögg and Brandstetter (2009) determined crystal structures of engineered 'superactive' FIXa variants (Y94F/K98T/Y177T, which improve the S4 substrate-binding subsite — the pocket hosting the substrate residue four positions N-terminal to the cleaved bond — and relieve the 99-loop occlusion, gaining several-thousand-fold activity toward small substrates), together with NaCl-soaked, ethylene-glycol-soaked, EDTA-soaked, and chloromethylketone-inhibited crystals (PDB entries 2WPH–2WPM). They reported: (i) the canonical Na+Na^{+} site remained unoccupied and proposed that a His185–Tyr225 hydrogen bond and the unusual 186-EGG-188 sequence motif (Glu186–Gly187–Gly188, with its Gly187 carbonyl orientation) block Na+Na^{+} coordination; (ii) a bound ethylene glycol (EG) molecule in a groove near the active site stabilizes a mature, FXa-like substrate-binding cleft, showing the active site's plasticity but leaving open whether a physiological protein or membrane contact occupies the same groove in vivo; (iii) Ca2+Ca^{2+}-linked structural changes ('dynamic fingerprints') traced through isomorphous difference Fourier maps — a crystallographic technique that subtracts matched data sets to localize structural differences — along communication lines between the Ca2+Ca^{2+}-binding loop and the active site, observed, however, in crystals carrying covalent active-site inhibitors such as FPR-CMK (D-Phe-Pro-Arg chloromethyl ketone, also called PPACK), which may dampen the full amplitude of the motions; and (iv) a general framework in which cofactor- and substrate-assisted activation is the release of internal brakes. The authors left open how these crystallographic observations translate into the physiological, membrane-bound, uninhibited Xase complex in solution — the question at the center of this problem.

Problem Statement

Establish the mechanism of the secondary, cofactor- and substrate-assisted activation of human coagulation factor IXa in its physiological context, replacing the crystallographic brake/communication-line picture of Zögg and Brandstetter (2009) — obtained on inhibited crystals of engineered superactive variants — with a mechanistic account valid for the uninhibited, membrane-bound intrinsic Xase complex in solution. Concretely, determine:

  1. The atomic organization of the membrane-associated FVIIIa–FIXa (and, ideally, FVIIIa–FIXa–FX) complex: which FVIIIa, membrane, and substrate contacts engage the FIXa protease domain, and whether proteinaceous or membrane contacts occupy the groove that ethylene glycol occupies in the 2009 structures and reproduce its activity-enhancing, stabilizing thermodynamic effect.
  2. The ion-linked allostery: whether and how physiological partners relieve the conformational elements that in the 2009 mutant structures gate the canonical Na+Na^{+} site (the His185–Tyr225 hydrogen bond and the 184/220-loop region including the 186-EGG-188 motif), what role Na+Na^{+} binding plays — alone and jointly with Ca2+Ca^{2+} — in the catalytic activity and cofactor affinity of FIXa within the Xase complex under physiological ionic conditions, and how the Ca2+Ca^{2+}-linked dynamic fingerprints seen in inhibited crystals manifest in the uninhibited complex.
  3. The energetic and temporal structure of the activation: the coupling free energies between cofactor binding, substrate and exosite binding (exosites are protease-surface binding sites outside the active-site cleft), and the conformational transitions of the FIXa protease domain, and the sequence in which these transitions occur during Xase assembly and substrate engagement.

The three numbered sub-questions above are jointly posed, and the task is an evidence-backed account of all three. A demonstrated refutation of a specific proposed element (for example, evidence that the sodium-site gating hydrogen bond is irrelevant to physiological Xase function) resolves only that element and is a partial contribution to the task, not a complete answer. The overall objective is a coherent, evidence-backed account of how FIXa's internal brakes are released in the physiological Xase complex — the completion boundary recognized by the field, since current reviews (2022–2026) still describe the structural organization of the membrane-bound Xase complex as largely unknown and the sodium/cofactor interplay as unsettled.

References

  1. Zögg T, Brandstetter H. Structural Basis of the Cofactor- and Substrate-Assisted Activation of Human Coagulation Factor IXa. Structure 17(12):1669–1678, 2009. DOI: 10.1016/j.str.2009.10.011. https://doi.org/10.1016/j.str.2009.10.011
  2. Brandstetter H, Bauer M, Huber R, Lollar P, Bode W. X-ray structure of clotting factor IXa: active site and module structure related to Xase activity and hemophilia B. Proceedings of the National Academy of Sciences USA 92(21):9796–9800, 1995. DOI: 10.1073/pnas.92.21.9796. https://doi.org/10.1073/pnas.92.21.9796
  3. Gopalakrishna K, Rezaie AR. The influence of sodium ion binding on factor IXa activity. Thrombosis and Haemostasis 95(6):936–941, 2006. DOI: 10.1160/th06-03-0156. https://doi.org/10.1160/th06-03-0156
  4. Hartmann R, Dockal M, Kammlander W, Panholzer E, Nicolaes GA, Fiedler C, Rosing J, Scheiflinger F. Factor IX mutants with enhanced catalytic activity. Journal of Thrombosis and Haemostasis 7(10):1656–1662, 2009. DOI: 10.1111/j.1538-7836.2009.03560.x. https://doi.org/10.1111/j.1538-7836.2009.03560.x
  5. Kristensen LH, Olsen OH, Blouse GE, Brandstetter H. Releasing the brakes in coagulation Factor IXa by co-operative maturation of the substrate-binding site. Biochemical Journal 473(15):2395–2411, 2016. DOI: 10.1042/BCJ20160336. https://doi.org/10.1042/BCJ20160336
  6. Fang H, Zögg T, Brandstetter H. Maturation of coagulation factor IX during Xase formation as deduced using factor VIII-derived peptides. FEBS Open Bio 9(8):1370–1378, 2019. DOI: 10.1002/2211-5463.12653. https://doi.org/10.1002/2211-5463.12653
  7. Vadivel K, Schreuder HA, Liesum A, Schmidt AE, Goldsmith G, Bajaj SP. Sodium-site in serine protease domain of human coagulation factor IXa: evidence from the crystal structure and molecular dynamics simulations study. Journal of Thrombosis and Haemostasis 17(4):574–584, 2019. DOI: 10.1111/jth.14401. https://doi.org/10.1111/jth.14401
  8. Freato N, Ebberink EHTM, van Galen J, Fribourg C, Boon-Spijker M, van Alphen FPJ, Meijer AB, van den Biggelaar M, Mertens K. Factor VIII-driven changes in activated factor IX explored by hydrogen-deuterium exchange mass spectrometry. Blood 136(23):2703–2714, 2020. DOI: 10.1182/blood.2020005593. https://doi.org/10.1182/blood.2020005593
  9. Basavaraj MG, Krishnaswamy S. Exosite binding drives substrate affinity for the activation of coagulation factor X by the intrinsic Xase complex. Journal of Biological Chemistry 295(45):15198–15207, 2020. DOI: 10.1074/jbc.RA120.015325. https://doi.org/10.1074/jbc.RA120.015325
  10. Childers KC, Peters SC, Lollar P, Spencer HT, Doering CB, Spiegel PC. SAXS analysis of the intrinsic tenase complex bound to a lipid nanodisc highlights intermolecular contacts between factors VIIIa/IXa. Blood Advances 6(11):3240–3254, 2022. DOI: 10.1182/bloodadvances.2021005874. https://doi.org/10.1182/bloodadvances.2021005874
  11. Kolyadko VN, Layzer JM, Perry K, Sullenger BA, Krishnaswamy S. An RNA aptamer exploits exosite-dependent allostery to achieve specific inhibition of coagulation factor IXa. Proceedings of the National Academy of Sciences USA 121(29):e2401136121, 2024. DOI: 10.1073/pnas.2401136121. https://doi.org/10.1073/pnas.2401136121
  12. Jiang S, Li F, Li L, Wang X, Wei D, Wu W, Xu Q. The Construction of a Molecular Model for the Ternary Protein Complex of Intrinsic Coagulation Pathway Factors Provides Novel Insights for the Pathogenesis of Cross-Reactive Material Positive Coagulation Factor Mutations. International Journal of Molecular Sciences 26(11):5191, 2025. DOI: 10.3390/ijms26115191. https://doi.org/10.3390/ijms26115191
  13. Ivanciu L, Camire RM. Blood Coagulation Factor IX: Structure, Function, and Regulation. IUBMB Life 77(5):e70024, 2025. DOI: 10.1002/iub.70024. https://doi.org/10.1002/iub.70024
  14. Mohammed BM. Structural determination of lipid-bound factor VIII. Journal of Thrombosis and Haemostasis 24(9):3182–3189, 2026. DOI: 10.1016/j.jtha.2026.05.021. https://doi.org/10.1016/j.jtha.2026.05.021